A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with a significant improvement in progression-free survival and a trend to an overall survival benefit, supporting progression to phase III randomized trials. | Stereotactic ablative radiotherapy for the comprehensive treatment of 1 3 Oligometastatic tumors SABR-COMET-3 Study protocol for a randomized phase III trial
